Talcum Powder & Ovarian Cancer Risk: Evidence

Using talcum powder in the genital area causes ovarian cancer.

In July 2024 the International Agency for Research on Cancer classified talc as probably carcinogenic to humans, its Group 2A category. The human evidence behind that decision was specifically about ovarian cancer. IARC pointed to numerous studies that consistently showed an increase in ovarian cancer among people who reported using body powder in the perineal region.

Group 2A is a statement about how strong the evidence is, not about how much risk any individual faces. IARC was careful about what it could not rule out. It graded the human evidence as limited rather than sufficient, because biases in how talc use was reported in the studies could not be ruled out with reasonable confidence, and because contamination of talc with asbestos could not be excluded in most of them. Asbestos is a known carcinogen that occurs naturally in the ground near talc deposits.

Study design matters a great deal here. Most of the studies showing a link asked women who already had ovarian cancer to remember powder use from decades earlier, then compared their answers with women who did not have cancer. People searching for an explanation for a diagnosis may recall past exposures differently. That is recall bias, and it can create an apparent association on its own.

Studies that recorded powder use before anyone became ill have generally been more reassuring. A pooled analysis of four large cohorts followed 252,745 women for a median of about 11 years. Ovarian cancer occurred in 61 per 100,000 person-years among women who had ever used genital powder, compared with 55 per 100,000 among those who had not. The hazard ratio was 1.08, with a confidence interval of 0.99 to 1.17, which did not reach statistical significance. The authors noted the study may still have been underpowered to detect a small increase.

More recent work has complicated the picture again. A 2024 analysis of the Sister Study that tried to correct mathematically for misreporting still produced estimates above 1.0. Meanwhile NCI's patient summary says studies of perineal talc have not found clear evidence of an increased risk of ovarian cancer, and FDA says a link has not been conclusively demonstrated and more research is needed.

Even taking the higher estimates at face value, the absolute difference is small. In the pooled cohort analysis, the estimated difference in ovarian cancer risk by age 70 was roughly 0.09 percentage points. Ovarian cancer is uncommon, and a modest relative increase in an uncommon disease is still an uncommon outcome.

A Group 2A label does not mean talc has been shown to cause ovarian cancer, and it does not mean past use has harmed you. There is no test or treatment recommended on the basis of talc use.

It also does not mean the question is settled in the other direction. The association keeps appearing, and IARC found it consistent enough to act on. And the label does not identify the culprit: if there is a real effect, asbestos contamination rather than talc itself remains a live explanation.

The honest answer is unproven. Studies consistently find somewhat more ovarian cancer among women who used genital talc, which is why IARC calls talc probably carcinogenic. But recall bias and possible asbestos contamination mean causation has not been established, and the absolute risk difference in the best-designed studies is small. Avoiding talc is a reasonable personal choice, and cornstarch-based powders are an alternative. If ovarian cancer risk is on your mind, the factors with the clearest evidence, including family history, BRCA1 and BRCA2 changes, and endometriosis, are the ones worth raising with your clinician.

• IARC press release 352: evaluation of talc and acrylonitrile (July 2024, PDF)
• NCI: Ovarian, Fallopian Tube, and Primary Peritoneal Cancers Prevention (PDQ) - patient version
• FDA: Talc in cosmetics